BiotechTube
Vascular Biosciences

Vascular Biosciences

San Diego, United States· Est.
vascularbiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Vascular Biosciences is a private, pre-revenue biotech firm founded in 2004 and based in San Diego. The company operates across three synergistic divisions: a pharmaceutical arm developing the CAR peptide for pulmonary hypertension, COVID-19, and sepsis; an interventional device arm with a novel endoarterial biopsy catheter; and a molecular diagnostics arm for analyzing biopsy samples. Its integrated approach aims to diagnose, monitor, and treat vascular diseases with greater precision, though its lead programs remain in pre-clinical and early development stages.

Pulmonary HypertensionSepsisCOVID-19Cardiovascular DiseaseAcute Respiratory Distress Syndrome

Technology Platform

CARSKNKDC (CAR) peptide for targeted tissue homing and drug enhancement; Endoarterial Biopsy Catheter for minimally invasive arterial tissue sampling; Molecular diagnostics for vascular disease profiling.

Opportunities

The integrated platform targets massive markets in pulmonary hypertension, sepsis, and vascular diagnostics with high unmet need.
The CAR peptide's ability to enhance existing drugs could accelerate development and create partnership opportunities with larger pharma companies.
The biopsy catheter could establish a new standard of care in precision vascular medicine.

Risk Factors

High technical risk as both the therapeutic peptide and novel biopsy device are unproven in humans.
The company faces significant financial risk as a pre-revenue entity developing multiple complex platforms concurrently.
Commercial adoption of the biopsy procedure requires changing clinical practice and demonstrating clear utility.

Competitive Landscape

In targeted pulmonary hypertension therapies, VBS would compete with established PAH drug developers (e.g., United Therapeutics, Johnson & Johnson) and new modalities. Its biopsy catheter faces limited direct competition but must prove superiority over standard imaging and hemodynamic measurements. The integrated diagnostic-therapeutic approach is relatively unique.

More companies in Diagnostics & Precision Medicine →More companies in United States →